The DOI matches its Crossref record; 203 of the 205 references it cites were found in a registry or an index.
Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel: This paper is also published in parallel in Archives of Medical Science [Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015; 11(1): 1–23]
Open accessAbstract
Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 - 15% of patients. In clinical practice, statin intolerance limits effective treatment of patients at risk of, or with, cardiovascular disease. Knowledge of the most common adverse effects of statin therapy that might cause statin intolerance and the clear definition of this phenomenon is crucial to effectively treat patients with lipid disorders. Therefore, the aim of this position paper was to suggest a unified definition of statin intolerance, and to complement the recent EAS statement on SAMS, where the pathophysiology, diagnosis and the management were comprehensively presented.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Self-citation2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management
Authors Task Force Members, Kristensen, S. D., Knuuti, J., Saraste, A., Anker, S. D., Bøtker, H. E., Hert, S. D., Ford, I., González‐Juanatey, J. R., Görenek, B., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu282 · Cited by 1,698
Self-citationThompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Research works printed but not linked: 14
- Banach M, 2009, Med Sci Monit, 15, MS1
- Colantonio LD, 2014, J Am Soc Nephrol
- Stroes ES, 2015, Eur Heart J
- 10.1016/S0025-6196(11)60897-5 · DOI
- 10.1016/j.taap.2012.01.008 · DOI · Paper page
- Gaitonde DY, 2012, Am Fam Physician, 86, 244
- Farias Moeller R, 2011, Case Rep Pediatr, 2011, 670673
- Bar SL, 2007, Can Fam Physician, 53, 428
- Balmer ML, 2008, Swiss Med Wkly, 138, 415
- Rysz J, 2006, Cell Mol Immunol, 3, 151
- Martin SS, 2013, Tresch and Aronow’s cardiovascular disease in the elderly, 121
- Banach M, 2015, Pharmacol Res
- Vandiver W, 2013, Fam Pract, 62, 730
- Adcock B, 2001, J Am Board Fam Pract, 14, 148
Cited by
Sorted by citations
Statin-Associated Side Effects
Thompson, P. D., Panza, G. A., Zaleski, A. L., & Taylor, B. A. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.071 · Cited by 776
Safety and efficacy of statin therapy
Adhyaru, B. B., & Jacobson, T. A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0098-5 · Cited by 424
Gender differences in the effects of cardiovascular drugs
Tamargo, J. L., Rosano, G. M. C., Walther, T., Duarte, J., Niessner, A., Kaski, J., Ceconi, C., Drexel, H., Kjeldsen, K. P., Savarese, G., et al. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw042 · Cited by 325
Cicero, A. F. G., Colletti, A., Bajraktari, G., Descamps, O. S., Djuric, D. M., Владиславович, Е. М., Fras, Z., Katsiki, N., Langlois, M. R., Latkovskis, G., et al. (2017) · Nutrition Reviews · doi:10.1093/nutrit/nux047 · Cited by 303
Self-citationThe Role of Nutraceuticals in Statin Intolerant Patients
Banach, M., Patti, A. M., Giglio, R. V., Cicero, A. F. G., Atanasov, A. G., Bajraktari, G., Bruckert, E., Descamps, O., Djuric, D. M., Ezhov, M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.040 · Cited by 272
Self-citation
Metadata
- Authors
- Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., Greenfield, R. S., Hovingh, G. K., Kostner, K., Serban, C., Lighezan, D., Fras, Z., Moriarty, P. M., Muntner, P., Goudev, A., Ceska, R., Nicholls, S. J., Broncel, M., Nikolic, D., Pella, D., Puri, R., Rysz, J., Wong, N. D., Bajnok, L., Jones, S. R., Ray, K. K., & Mikhailidis, D. P.
- Affiliations
- Medical University of Lodz (PL)
- University of Palermo (IT)
- University of Chicago (US)
- Westchester Medical Center (US)
- University of Belgrade (RS)
- Amsterdam UMC Location University of Amsterdam (NL)
- The University of Queensland (AU)
- Victor Babeș University of Medicine and Pharmacy Timișoara (RO)
- University of Ljubljana (SI)
- University of Kansas Medical Center (US)
- University of Alabama (US)
- Queen Giovanna Hospital (BG)
- South Australian Health and Medical Research Institute (AU)
- University of Pavol Jozef Šafárik (SK)
- Indraprastha Apollo Hospitals (IN)
- University of California, Irvine (US)
- Johns Hopkins Medicine (US)
- Imperial College London (GB)
- The Royal Free Hospital (GB)
- ORCID
- Banach, Maciej
- Rizzo, Manfredi
- Toth, Peter P
- Farnier, Michel
- Davidson, Michael H
- Aronow, Wilbert S
- Djuric, Dragan M
- Hovingh, G Kees
- Lighezan, Daniel
- Fras, Zlatko
- Moriarty, Patrick M
- Muntner, Paul
- Goudev, Assen
- Nicholls, Stephen J
- Broncel, Marlena
- Pella, Daniel
- Puri, Raman
- Rysz, Jacek
- Wong, Nathan D
- Jones, Steven R
- Ray, Kausik K
- Mikhailidis, Dimitri P
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2015-04-24
- Volume
- 14
- Issue
- 6
- Pages
- 935-955
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2105307761
- Cited by
- 162
- References
- 205
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 6 · 2023: 13 · 2022: 13 · 2021: 10 · 2020: 14 · 2019: 12 · 2018: 21 · 2017: 25 · 2016: 24 · 2015: 10
- FWCI
- 26.88
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- other-oa
- Locations
- Expert Opinion on Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statin intolerance, statin-associated muscle symptoms, statin adverse effects, lipid metabolism disorders, cardiovascular disease prevention, statin therapy
- MeSH terms
- Cardiovascular Diseases, Humans, Muscular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
